loading page

A SURVEY ON ITALIAN MEDICALS DURING COVID-19 OUTBREAK. COULD BACILLUS CALMETTE-GUÉRIN VACCINE BE EFFECTIVE AGAINST SARS-COV2?
  • +4
  • Vincenzo Patella,
  • Alessandro Sanduzzi,
  • Dario Bruzzese,
  • Giovanni florio,
  • Raffaele Brancaccio,
  • Gabriella Fabbrocini,
  • Gabriele Delfino
Vincenzo Patella
Presidio Ospedaliero Santa Maria della Speranza di Battipaglia
Author Profile
Alessandro Sanduzzi
Department of Clinical Medicine and Surgery, Section of Respiratory Disease, University of Naples Federico II
Author Profile
Dario Bruzzese
University of Naples Federico II Department of Public Health
Author Profile
Giovanni florio
Presidio Ospedaliero Santa Maria della Speranza di Battipaglia
Author Profile
Raffaele Brancaccio
Presidio Ospedaliero Santa Maria della Speranza di Battipaglia
Author Profile
Gabriella Fabbrocini
Department of Clinical Medicine and Surgery, Dermatology, Section of Dermatology, University of Naples Federico II
Author Profile
Gabriele Delfino
Presidio Ospedaliero Santa Maria della Speranza di Battipaglia
Author Profile

Abstract

Background: Epidemiological studies show that BCG vaccinated population seems to be more likely protected from COVID-19 infection, but WHO gave a stark warning on use of BCG vaccine without confirmed COVID-19 trials. The aim of this survey is to assess the ability and readiness to respond to viral infection by physicians who had been BCG vaccinated. Methods: After Ethical Committee authorization, professional orders were used to contact physicians with an online survey. Specialty, COVID-19 infection, and previous BCG vaccination were recorded. Statistical data analysis was performed. Results: 1906 medicals answered the questionnaire, (M=1068; F=838; mean age 50.7+/-13.3; >24<87 yrs), more than half (1062; 55.72 %) experienced BCG vaccination. Professional activity was recorded, and only 49 subjects (2.57%) of them was infected by SARS-CoV2. Among the group of infected people, asymptomatic form occurred in 12 subjects (24.5%); a pauci-symptomatic form in 24 subjects (49.0%); a severe form (pneumonia and/or respiratory distress) in 13 (26.5%). SARS-CoV2 infection rate was 2.17% (23/1062) in vaccinated group and 1.66 % (14/844) in unvaccinated group (p=0.359). Conclusion: Our experience does not confirm the possible protective role of BCG against COVID-19, pending ongoing controlled trials. Although recent epidemiological studies point out in BCG vaccinated population a lower prevalence of SARS-CoV2 infection, in our cohort of physicians no significant difference was found in terms of prevalence of COVID-19 infection. Our data underline the necessity to follow the WHO warning about indiscriminate use of BCG vaccine, until clear evidence of protection by BCG vaccination against COVID-19 is fully demonstrated.